INFANT Seminar Series: Dr Mark O’Sullivan to Discuss Neonatal EEG Monitoring – Hardware, AI and Medical Device Design

By |2022-03-22T10:34:57+00:00March 22nd, 2022|

Our next INFANT seminar will be this Friday, March 25th at 12pm, when Dr Mark O’Sullivan will present “Neonatal EEG monitoring – hardware, AI and medical device design”.

Dr O’Sullivan will present updates on the Neurobell Project, which aims to develop a portable neonatal EEG monitor with seizure detection, including methodologies for medical device design in a quality and regulatory compliant manner.

Lastly, Dr O’Sullivan will present new research from the Delphi Project on the design of an artefact detection algorithm for neonatal EEG and its impact on automated HIE grading.

For privacy reasons YouTube needs your permission to be loaded.

Read More

INFANT Seminar Series: Dr Dhanis Lad to Discuss the STOP AD Randomised Controlled Trial

By |2022-03-09T14:31:21+00:00March 9th, 2022|

Presentation title: Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants – the STOP AD randomised controlled trial

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition, characterized by dry, red and itchy skin. AD usually begins in infancy and affects up to one fifth of children. Evidence of its pathogenesis implicates impaired skin barrier function as a significant pathomechanism, along with cutaneous immune dysregulation and microbial disturbances.

Emollients are moisturising treatments applied directly to the skin to soothe and hydrate it. Daily emollient use is a cornerstone of AD management. Recently, the spotlight has been on the potential role of emollients in infancy in preventing AD.

Short-term Topical Application to Prevent Atopic Dermatitis (STOP AD) was a single-centre, two-armed randomized control trial that postnatally recruited newborn infants at high-risk of AD. This study aimed to investigate if daily emollient use from birth to 2 months can reduce the incidence of AD in high-risk infants. Recruitment took place between April 2019 and November 2020 in Cork University Maternity Hospital (CUMH).

Infants were randomised within 4 days of birth to either twice-daily emollient application for the first 8 weeks of life (intervention) or to standard routine skin care advice (control group). The primary outcome was cumulative incidence of AD at 12 months. Secondary outcomes included AD incidence at 6 months, cumulative incidence of sensitization to food at 12 months and the evolution of TEWL and natural moisturising factor (NMF) between 0-12 months.

Read More

INFANT Seminar Series: Dr Kirsten Dowling to Discuss Predictive Biomarkers for Autism Spectrum Disorder: A Metabolomics Profiling Study in the Cork BASELINE Birth Cohort

By |2022-02-09T15:45:36+00:00February 9th, 2022|

Autism Spectrum Disorder (ASD) is a neurological, developmental disorder that affects communication and behaviour. Currently, there is a lack of understanding about the aetiology of ASD and children are not diagnosed reliably until they are at least 3 to 4 years of age. Henceforth, there is an urgent need for the identification of diagnostic biomarkers for the prediction of ASD. 

Metabolomic profiling was undertaken on cord blood plasma from ASD cases vs gender matched controls from the Cork BASELINE Birth Cohort using Liquid chromatography-tandem mass spectrometry.

Clinical data (maternal and child BMI, birth weight, gestational age, health and lifestyle etc.) were combined with metabolite peaks to explore machine learning (ML) algorithms: t-test, partial least squares-determinant analysis (PLS-DA) and random forest (RF).

We profiled 2612 compounds and 18 clinical variables to identify the top predictive metabolite and clinical features for the development of ASD.  RF feature selection resulted in the highest performing 20 metabolite subset, and pathway analysis revealed significant alterations in 5 metabolic pathways.

Dr Kirsten Dowling will deliver her presentation on Friday, February 11 at 12 pm.

Read More

INFANT Seminar Series: Dr Colin Hawkes to Discuss His Research Into Diabetes

By |2022-01-13T10:15:42+00:00January 13th, 2022|

Our INFANT seminars will resume on Friday, January 28th at 12pm. We are delighted to welcome Dr Colin Hawkes, paediatric endocrinologist as our first speaker of the new year.

 Dr. Hawkes will present  Clinical & Academic Synergies in Type 1 Diabetes.

He will discuss a selection of his past and ongoing diabetes research at the Children’s Hospital of Philadelphia and Cork University Hospital, as well as future opportunities.

 We hope you can all join us for what we are sure will be a fantastic talk!

Read More

INFANT Seminar Series: Dr Andrea Bowe and Dr Roberto Chioma To Present Their Research Plans

By |2021-12-06T10:39:55+00:00December 6th, 2021|

The final INFANT seminar series before Christmas will take place this Friday at 12 noon. Two of our new research fellows will present their research plans.

Dr. Andrea Bowe, an ICAT fellow will be discussing her PhD ‘Predicting Cognitive Outcomes In Childhood – Exploring the Role for Machine Learning’.

Dr. Roberto Chioma, a visiting Italian clinical fellow, will be discussing the early echocardiographic assessment of transitional hemodynamics.

We hope as many of you can attend and welcome our new INFANT members.

Read More
This website uses cookies and third party services. Settings
Ok

INFANT Cookie Consent

INFANT uses cookies and similar technologies to deliver, maintain, and improve our services. Some are necessary to help websites work properly, can’t be switched off and do not require consent, and some are optional but support INFANT and your experience in other ways. You can find out more in our privacy policy and cookie policy, and manage the choices available to you at any time by going to these links which are repeated at the bottom of every page. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyse site usage, and assist in our marketing efforts. This option will include cookies which transfer data outside GDPR territory. Use the Cookie Preferences option to see more information and customise your choices.
Go to Top